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A Meeting of the
Minds on Mice
If genetics research is ever to fulfill its
promise of revolutionizing medicine, geno-
types must be linked to phenotypes—that is,
individual genomic characteristics must be
identified and associated with outcomes in
the forms of disease susceptibility and/or
development; individual responses to drugs,
infectious agents, or environmental expo-
sures; or other individual characteristics such
as behavioral tendencies. Why does the per-
son who never smoked develop lung cancer,
while the three-pack-a-day smoker remains
healthy? Why do some people become
addicted to drugs, while other users are never
hooked? Why does a particular medication
work wonders in some people, but not work
at all in others? These and countless similar
questions represent the enormous challenge
still facing researchers as they strive to make
personalized medicine a clinical reality. 
The answers to many of these questions
may yet be discovered in the genomes of
mice, our diminutive mammalian relatives.
That’s certainly the hope and belief of the
members of the mouse genetics community,
180 of whom gathered 6–9 May 2006 in
Chapel Hill, North Carolina, for the fifth
annual meeting of the Complex Trait
Consortium (CTC), a loosely woven interna-
tional organization tightly knit in its dedica-
tion to elucidating human characteristics by
identifying their genetic counterparts in mice.
The “complexity” of complex traits
derives from the fact that they are poly-
genic—multiple genes interact to cause these
conditions, and the genes involved may not
interact additively. Ninety-three reports pre-
sented at the CTC meeting updated progress
in the hunt for the multiple genes and quan-
titative trait loci (or chromosomal “hot
spots”) associated with a wide variety of com-
plex traits such as heart failure, tumor resis-
tance, obesity, drug and alcohol addiction,
and schizophrenia. Sponsored by the
NIEHS, the UNC–Chapel Hill, and Agilent
Technologies, the conference brought togeth-
er a diverse group of mouse geneticists, mole-
cular biologists, statisticians, and bioinfor-
maticists from 10 countries. 
The CTC is all about collaboration and
interaction. “It’s unquestionably the best
meeting that I go to every year,” says
Abraham Palmer, an assistant professor of
human genetics at the University of Chicago.
“The opportunities to communicate with
other geneticists working in other fields and
with the people who develop our methodol-
ogy are critically important, and accelerate by
months or even years the rate at which the
field can move forward,” he says. 
Karlyne Reilly, a principal investigator in
the Mouse Cancer Genetics Program at the
National Cancer Institute, agrees. “It brings
together a wide variety of science around
techniques and how you solve the problems
that are common to these different areas,”
she says. “I always come away with new tools
to play with, that I can apply to my own
research.”
Building a Better Mouse Line
The CTC is presently at the midpoint of
building a resource that should prove enor-
mously valuable in the effort to associate
genotypes with phenotypes. The Collab-
orative Cross (CC) is a carefully planned and
controlled mouse recombinant inbreeding
program that began in 2005 with eight genet-
ically heterogeneous strains. Upon its expect-
ed completion in about four years, 1,000
lines closely modeling the breadth of human
genetic diversity will have been generated.
According to conference keynote speaker
Jean-Louis Guénet, a professor emeritus of
mouse genetics at the Institut Pasteur in
Paris, it will be “one of the most important
pages in the book of genetics of the future.”
Armed with several powerful new bioin-
formatic and biostatistical tools being devel-
oped specifically to take full advantage of the
resource, the CC will enable researchers to
hunt far more precisely and efficiently for the
multiple genes and quantitative trait loci that
constitute complex traits, and will allow the
community to share and integrate their raw
data sets far more effectively. 
“The idea is to accumulate as much
diverse data as possible for relatively fixed
strains, what we call the ‘genetic reference
population,’” says Robert Williams, a profes-
sor of anatomy and neurobiology at the
University of Tennessee Health Science
Center and one of the founders of the CTC.
“The hope is that everybody will use their
own tools—their own methods and their
own phenotypes—but the Collaborative
Cross will provide a way to bind those results
together by using the same animal resource.”
According to conference co-organizer
David Threadgill, an associate professor of
genetics at UNC–Chapel Hill, the goal is for
the CC to evolve to become “the central
resource for experimental mammalian biolo-
gy.” With a fixed genetic reference popula-
tion and common tools, he says, “it will be
the resource that everybody turns to,”
because every piece of data collected through
the CC will be immediately comparable to
any other piece of data in the database. 
CC Riding
The CC will enable a so-called systems genet-
ics approach, as opposed to the traditional,
laborious effort to identify one gene at a time.
As Guénet points out, diseases that are the
consequences of the alteration of a single
gene—one example is cystic fibrosis—tend to
be marginal in terms of frequency. However,
polygenic diseases tend to be much more
widespread, he says: “Next door to you, you
probably have someone with asthma, der-
matitis, or autoimmune disease. . . . So we
have to work hard to understand the genetic
determinants of these complex diseases, and
presumably what we are going to learn from
the mouse can be transposed to the human
being, because we share ninety-eight percent
of our genes with the mouse.”
Williams shares Guénet’s optimism
about the tremendous potential of the CC
to shed useful light on common human dis-
eases. “You have to understand the function
of the gene and its products in a complex
milieu, in a mouse or human—not only a
mouse or human, but many different mice
and many different humans,” he says. “We
think [the CC] will provide the resource to
do that.” He adds that the ability to conduct
experimental population-based research with
the CC should allow much more compre-
hensive exploration of the genetics associat-
ed with gene–environment interactions.
That exploration will also be enhanced
by the completion of a mouse genetics initia-
tive undertaken by the NIEHS and Perlegen
Sciences to identify the genetic variants in
15 diverse strains of laboratory mice, includ-
ing SNPs (single-nucleotide polymor-
phisms), indels (insertions/deletions), and
haplotypes (blocks of related SNPs). The
database, a project of the recently established
NIEHS Center for Rodent Genetics, is
scheduled to be unveiled in September
2006, and is anticipated to be a rich and
robust source of information for the mouse
genetics community.
Signs of early but significant progress in
the CC initiative were among the highlights
of the meeting. Conference co-organizer
John E. French, an NIEHS research physi-
ologist, is encouraged by results emerging
from pilot studies. “There’s at least been a
proof of principle established that it’s going
to be a very effective tool,” he says. “We are
only seeing the beginning evidence of that—
there’s a long way to go—but some of the
promise has been identified and, I think,
validated.” According to Williams, the pilot
project is now of sufficient size (two recom-
binant inbred sets, LXS and BXD, with 80
member strains) that “it provides the com-
munity with a good flavor of what this will
look like when we have an order of magni-
tude more strains than we do now.”
Threadgill is excited by the flavor that’s
already emerging. “The major things that
are starting to come out are the results of
integrating data sets, integrating genetic
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patterns,” he says. The new knowledge
that’s coming out of that—the identity of
new genes that are potential master modu-
lators of genetic networks, and how those
may actually also be very important for
mediating disease processes—speak to the
remarkable potential that will be realized
when the CC is completed.
A Case in Point
Research results presented by Palmer on his
group’s work at the University of Chicago
illustrate the broad outlines of the types of
studies being undertaken by mouse geneti-
cists. Palmer and colleagues are investigat-
ing the genetic underpinnings of suscepti-
bility or resistance to drug addiction; given
today’s working definition of “the environ-
ment,” recreational drug use is fast becom-
ing a xenobiotic exposure of great interest.
An understanding of the genotypic differ-
ences between addiction susceptibility and
resistance could lead to new targets for ther-
apeutic drugs or preventive interventions.
The team selectively bred mice to have
very high or very low sensitivity to locomo-
tor stimulation, a particular behavioral
effect of methamphetamine that is a charac-
teristic animal response to drugs of abuse.
They then measured the expression of more
than 14,000 genes in a region of the ani-
mals’ brain known to be involved in
response to the drug. Ultimately, they
arrived at a candidate gene that was found
to be very differentially expressed in the
high- and low-sensitivity mice—casein
kinase 1 epsilon (Csnk1e). It was a gene
already known to be involved in locomotor
stimulant response of animals to various
drugs. But the question then became, was it
important in humans?
Fortuitously, thanks to colleague
Harriet de Wit of the University of Chicago
Department of Psychiatry, Palmer had
access to DNA from a cohort of 100
healthy human volunteers. In a double-
blind study, the subjects received 0-, 10-,
and 20-mg doses of amphetamine in a ran-
domized order. Responses were measured
by standardized questionnaires, and were
then compared to results of genotyping
tests, to see whether there was a correlation
between response to the drug and polymor-
phisms in Csnk1e.
“We found a statistically significant
association between this gene, Csnk1e, and
people’s sensitivity to the euphoric effects of
the drug,” says Palmer. “So the people with
one genotype ‘got a buzz,’ while people
with another genotype didn’t. We hypothe-
size that that may have implications for the
likelihood of a person with one genotype
who samples the drug to continue to use
the drug, and that of course would put
them at grave risk for developing an abusive
relationship with the drug.”
Palmer suspects that polymorphisms in
Csnk1e may also be important in a variety
of other systems whose mechanisms might
be similar to that of addiction. These
include the manic phase of bipolar disorder
and the use of stimulants to treat attention
deficit/hyperactivity disorder.
“I think we’re now at a point where it’s
just about to become easy to go from a phe-
notype to identifying some of the genes that
are involved in that phenotype,” says Palmer.
“To get all of them is going to take longer,
and it’s going to require further refinements
in our methodology, but I actually think that
the story I told is going to become a com-
mon story. . . . In the same way that molecu-
lar biology took a long time to mature, and
now is unbelievably central to the way we
think about the progress of medicine and
health sciences, I think this field of genetics
is right at that turning point.”
Knowledge gained from the genomes of
our mammalian cousins by groups like the
CTC may provide the vital information to
eventually usher in the much-anticipated era
of personalized medicine. Says Threadgill,
“What it really comes down to is being able
to predict which individuals are going to be
susceptible to certain environmental expo-
sures or disease processes, which individuals
are going to respond adversely to combina-
tions of alleles, so that interventions and pre-
ventive medicine can be applied where they
need to be applied, rather than in global
fashion.” –Ernie Hood
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Culling out complex traits. A consortium of international scientists is launching new mouse
research initiatives to help elucidate genetic components of complex human diseases.Environmental
Polymorphism
Registry
Banking DNA to Discover the
Source of Susceptibility
Walking outside on a day when ozone levels
are at “code orange” doesn’t bother one per-
son, but for someone else, it can result in
chest pain, coughing, wheezing, or lung and
nasal congestion. Why? Polymorphisms, tiny
interindividual variations in genes, may be
part of the reason. Providing a pool of
information to help researchers determine
how these variations interact with the
environment to cause disease is the ultimate
goal of the Environmental Polymorphism
Registry (EPR), which is sponsored by the
NIEHS and conducted in collaboration with
the University of North Carolina at Chapel
Hill’s General Clinical Research Center. 
Any North Carolinian over 18 years of
age can donate a sample—about a table-
spoon of blood—to the EPR. Rather than
recruiting donors with a particular disease,
the EPR aims to gather, over five years, sam-
ples from 20,000 people who represent the
general state population. The regional
nature of the effort facilitates recruitment
and follow-up. 
“Recruitment is monitored to ensure that
the EPR population is representative of the
North Carolina population,” says Patricia
Chulada, one of the four principal investiga-
tors of the EPR and a health scientist admin-
istrator at the NIEHS. “If we see deficiencies
in certain groups, then we can increase
efforts targeted to those particular groups.” 
This approach will help researchers find
out which polymorphisms are most com-
mon. “We want to look at people’s genetic
material and find variations, and then go
back and figure out what those variations
mean,” says another EPR principal investiga-
tor, Paul B. Watkins, a professor of medicine
at UNC–Chapel Hill and director of the
General Clinical Research Center.
Chulada and Perry Blackshear, the
NIEHS director of clinical research, initiated
the registry by approaching Watkins and
Susan Pusek, director of training and career
development at the General Clinical
Research Center. Watkins says the insti-
tute—and Blackshear himself—realized that
“this is an essential direction of research to
understand why some people are healthy and
some are sick.”
There are multiple DNA registry efforts
in the United States. Two major DNA bank-
ing efforts include Northwestern University’s
NUgene Project and the Marshfield Clinic’s
Personalized Medicine Research Project,
both launched in 2002. International DNA
banks are even more common, Chulada says.
For instance, Iceland’s deCODE Project has
recruited more than 80,000 subjects and has
published findings on genes associated
with arthritis and many other common
conditions. 
The EPR is unique, however, because it
is designed to focus on environmentally
responsive genes—those that increase the
risk of disease when combined with an envi-
ronmental exposure. The registry was creat-
ed with the express intent of facilitating clin-
ical studies of polymorphisms in these genes.
Being affiliated with the NIEHS, where sci-
entists are already studying such interac-
tions, makes the EPR a natural resource for
these investigations. 
Protecting Participants
Unlike with anonymous DNA databases,
EPR donors provide their names and con-
tact information so they can be asked to par-
ticipate in follow-up studies if their DNA
contains a polymorphism of interest.
Participation in follow-up studies is option-
al, and donors can drop out of the database
at any time. 
Donors learn about the steps taken to
ensure confidentiality in a 6-page consent
form. Study interviewers at recruitment
tables also discuss this information with
potential donors, Chulada says.
Donors’ names and other information
are stored separately from samples. When a
sample is collected, it’s assigned a personal
identification number. The code key that
links the sample to identifying information
is kept separate from the sample and from
all other data in a computer system that’s
password-protected. Access to this system is
limited to only a few people directly
involved in the EPR. Researchers can obtain
contact information for potential partici-
pants only after approval by the EPR
Oversight Committee.
To receive samples, researchers must
sign a material transfer agreement, in which
the researcher’s institution agrees to several
conditions. “They can only use the samples
for what they outlined in the agreement,”
Chulada says. “They can’t give the samples
to others. And they have to destroy the sam-
ples within a certain amount of time [which
varies on a case-by-case basis].” 
In addition, the NIH has granted the
EPR a Certificate of Confidentiality, which
protects researchers from being required,
even by subpoena, to disclose research data
or other information about an individual to
an outside party such as an insurance com-
pany, an employer, or a civil or criminal
court. “This is another layer of protection
built into this system,” Chulada says. 
Stepping Up Recruitment
The EPR has already accumulated about
4,000 samples—not far behind the 5,000
collected by NUgene since its launch. The
A 408 VOLUME 114 | NUMBER 7 | July 2006 • Environmental Health Perspectives
NIEHS News
D
o
n
a
 
M
c
N
e
i
l
l
/
N
I
E
H
S
A little prick for a big cause. The Environmental Polymorphism Registry aims to collect 20,000 blood
samples that will be studied to help determine how genetic differences may result in disease.EPR’s goal of 20,000 samples is the mini-
mum needed to conduct certain types of
studies with adequate statistical power,
Chulada says. For example, if a researcher
was interested in a rare genetic variant that
occurs in only 1% of the population, the
variant should be present in 200 samples
from a registry of 20,000. “That would give
us adequate statistical power to test for a phe-
notypic association of low to moderate effect,
depending on other factors,” Chulada says.
When the EPR began, it recruited exclu-
sively at two clinics at UNC–Chapel Hill. It
has since expanded recruitment to Rex
Hospital in Raleigh and is applying for
approval to recruit at Duke University
Medical Center in Durham. However,
Chulada says, “Although recruiting at med-
ical clinics gave us a diverse population in
terms of health and other characteristics, we
learned that we could increase both recruit-
ment rates and diversity by recruiting out-
side of the clinic setting.” 
A recruitment fair held for five days at the
NIEHS campus in Research Triangle Park
yielded about 420 donors. “We were ecstatic
with the response of the NIEHS communi-
ty,” Chulada says. The general public also can
donate through study drives at corporations
and health fairs in Research Triangle Park.
Potential participants can visit the EPR web-
site (http://dir.niehs.nih.gov/direpr/) to find
out about upcoming drives.
A DNA Goldmine
John Hollingsworth, a scientist working in
the Environmental Lung Disease Group in
the NIEHS Laboratory of Respiratory
Biology, is one of the first investigators to
apply for use of EPR samples. Hollingsworth
and colleagues want to identify people who
have a polymorphism in a certain gene, Toll-
like receptor 4 (TLR4), known to be impor-
tant in innate immune responses.
TLR4 was first identified as a candidate
gene for response to ozone by NIEHS scien-
tist Steven Kleeberger, leader of the
Environmental Genetics Group in the
Laboratory of Respiratory Biology.
Subsequently, Hollingsworth and colleagues
have demonstrated that mice deficient in
TLR4 are protected against airway hyper-
responsiveness after exposure to ozone. “We
want to determine if this gene is important
in people in the biologic response to inhaled
ozone,” Hollingsworth says. “We’re trying
to validate what we’ve seen in mice in a
human cohort.” 
Hollingsworth calls the EPR a “gold-
mine.” He says, “It’s a perfect situation. We
have a cohort willing to be genotyped,
rather than doing a mass screening of people
for a single project, which is what we’ve had
to do in the past.” –Angela Spivey
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Headliners Autism
NIEHS-Supported Research
Misfolded Protein Presents Potential Molecular Explanation for
Autism Spectrum Disorders
De Jaco A, Comoletti D, Kovarik Z, Gaietta G, Radic ´ Z, Lockridge O, et al. 2006. A muta-
tion linked with autism reveals a common mechanism of endoplasmic reticulum reten-
tion for the α,β-hydrolase fold protein family. J Biol Chem 281:9667–9676.
Currently, there is only very limited information available on the etiology
and biological basis of the autism spectrum disorders, although a mutation
in the neuroligin 3 gene has caught researchers’ attention in recent studies.
Now NIEHS grantees Mark H. Ellisman and Palmer Taylor at the University
of California, San Diego, and their colleagues have determined that homol-
ogous mutations in the genes coding the proteins butyrylcholinesterase
(BChE) and acetylcholinesterase (AChE) cause defects in protein expression
similar to those seen with neuroligin 3, shedding further light on a poten-
tial molecular mechanism underlying autism.
The neuroligins, BChE, and AChE are members of the α,β-hydrolase fold
family of proteins. The neuroligin 3 mutation, an arginine-to-cysteine sub-
stitution, was identified in a set of twins and has been shown to result in
most of the expressed protein being retained within the endoplasmic retic-
ulum. The small amount of protein that does reach the surface of the cell
shows little binding affinity for its partner, β-neurexin, suggesting possible
misfolding of the protein. Misfolded proteins are known to cause endoplas-
mic reticulum stress. This, in turn, can trigger cell death and contribute to
human diseases including neurodegeneration, heart disease, and diabetes
mellitus. 
In the current study, the researchers used confocal fluorescence
microscopy and analysis of oligosaccharide processing to observe whether
an arginine-to-cysteine mutation affected AChE and BChE similarly despite
the proteins having differing oligomerizing capacities. By inserting homolo-
gous mutations in the AChE and BChE cDNAs, they found that the mutation
also resulted in endoplasmic reticulum retention of the two cholinesterases.
The proteins were then likely degraded in the proteasome. The authors
speculate that altering intracellular oxidation/reduction parameters may
assist in the proper folding and export of these proteins. –Jerry PhelpsMany people find it hard to fit professional
development and continuing education
into their busy work lives. Now help is just
a mouse-click away for nurses seeking flexi-
ble, self-paced training in the growing field
of environmental genetics. The Commun-
ity Outreach and Education Core (COEC)
of the Center for Environmental Genetics
at the University of Cincinnati, in collabo-
ration with the Genetics Education
Program for Nurses (GEPN) of Cincinnati
Children’s Hospital Medical Center, has
created an online Environmental Genetics
and Complex Diseases educational module
that introduces nurses to the principles of
environmental genetics, and also teaches
them how to apply those principles in
nursing practice. 
Online since December 2005, the
module is useful for all nurses in clinical
practice, but especially targets those who
work extensively with minority or med-
ically underserved patients. The module
focuses on alcoholism, lead, and asthma,
three challenging public and environ-
mental health problems in underserved
communities. 
“The module is designed to prepare
nurses in underserved communities to
identify people who are at risk for envi-
ronmental genetic conditions and help
those people gain access to community
services that emphasize prevention and
early treatment strategies,” says COEC
director M. Kathryn Brown.
Cynthia Prows, a clinical nurse special-
ist in genetics and the principal investiga-
tor of the web program, says the module
organizes information into useful and
manageable resources. “There is a tremen-
dous amount of information
on the Internet about genetics
and about environmental
health. But how do nurses who
have limited knowledge in the
topic areas locate the various
sites, sift through all the infor-
mation, decide what informa-
tion is current and accurate,
and then use that information
for learning purposes? The
answer is, most nurses don’t
because they don’t have the
time or the necessary founda-
tional knowledge in genetics to
mine the overwhelming mass
of information that is accessi-
ble through the Internet.” 
The module developers
have done that work for the
nurses, and have organized the
content in a way that helps
nurses develop foundational
knowledge in environmental genetics
using high-quality resources that are
applicable to their practice. Once learners
create a unique username and password,
they can access the module free of charge,
and can re-enter it at any time at the place
they last exited. Those who wish to earn
4.8 nursing continuing education contact
hours after completing the module and
associated evaluations pay a minimal pro-
cessing fee. 
The module offers nurses background
information on gene–environment interac-
tions, and teaches them environmental and
sociodemographic risk factors for common
diseases. It also provides screening tools
and community resources for nurses treat-
ing patients with recognizable genetic and
environmental risk factors. Each of the
three learning tracks also offer prenatal,
pediatric, and adult case studies and self-
assessments with each content area.
After completing the module, nurses
are able to approach their communities
armed with valuable knowledge of
gene–environment interactions and insight
into how those interactions can affect
human health. They are also equipped
with a wealth of online resources that can
be accessed long after they complete the
training module. 
“Making sense of the fast-growing lit-
erature about how the health impacts of
environmental exposures through the life
span are mediated by our genetics is a chal-
lenge for health care professionals,” says
Brown. “We hope that the vast array of
resources identified in these self-paced,
online modules will be helpful to primary
care practitioners trying to make sense of
new developments in genetic screening
tests, environmental prevention strategies,
and treatment options.” 
The module is available at http://
gepn.cchmc.org/. Three additional genet-
ics education modules currently available
include Promoting Informed Decision-
Making about Genetic Testing, Ethical and
Social Issues Related to Genetic Testing,
and Interpreting Family History. Two new
modules are also in the pilot testing phase:
Genetics Is Relevant Now––Nurse Views
and Patient Stories, and Nurses’ Role in
Pharmacogenetics/Pharmacogenomics.
–Tanya Tillett
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New age of nursing. An online continuing education mod-
ule introduces nurses to principles of environmental genetics
and shows them how to put such principles into practice.
BEYOND THE BENCH
Continuing Education for Nurses on
Environmental Genetics and Complex
Diseases